我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 奥洛兹美医疗
相关临床试验
9
0 进行中
药物批准
10
批准总数
监管机构
1
监管机构数
成立时间
1979
已完成
100.0%
FDA
Food and Drug Administration
- TransCode Therapeutics, a clinical-stage immuno-oncology and RNA therapeutics company, has appointed Jack E. Stover to its Board of Directors effective December 22, 2025. - Stover brings over three decades of executive leadership experience across life sciences companies, including successful exits such as leading Antares Pharma's sale to Halozyme for over $900 million. - The appointment strengthens TransCode's leadership as the company advances its RNA and immuno-oncology pipeline for treating high-risk and advanced cancer patients. - Stover will join the Audit and Nominating Committees as the company enters what leadership describes as an exciting stage of development.
